Clinical Trial

Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2025 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to identify the characteristics of brain functional connectivity in refractory constipation and fluoxetine-sensitive patients. The main questions it aims to answer are: * Investigating the alterations in brain functional connectivity in patients with refractory constipation and fluoxetine-sensitive patients * Assessing the predictive value of brain functional connectivity regarding the efficacy of fluoxetine and standard protocol treatments for constipation. Participants will receive: * Standard physiological and psychological assessments of constipation * BOLD-fMRI tests * Standard protocol and fluoxetine treatment If there is a comparison group: Researchers will compare: Refractory group/Fluoxetine sensitive group to see the specific brain alterations.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-01-14; most recent amendment 2025-07-22.
Trial Details
NCT Number NCT06221722
Lead Sponsor Xijing Hospital of Digestive Diseases
Conditions Constipation - Functional, Refractory Constipation, Fluoxetine, fMRI, Brain Connectivity, Treatment Efficacy, Somatic Symptom, Mental Symptom
Enrollment 150 participants
Start Date 2023-11-01
Primary Completion 2025-09-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-24